You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 133 No. 6, June 1974 TABLE OF CONTENTS
  Archives
  •  Online Features
  SYMPOSIUM ON HYPERTENSION
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Vasodilator Drugs in the Treatment of Hypertension

Jan Koch-Weser, MD

Arch Intern Med. 1974;133(6):1017-1027.


Abstract

Treatment with vasodilating drugs specifically reverses the major hemodynamic abnormality of primary hypertension. Hypotensive effectiveness of vasodilators is limited by three responses of hypertensives to vasodilation-induced blood pressure reduction, including reflex increases in sympathetic activity that raise cardiac output, augmentation of plasma renin activity, and sodium retention with plasma volume expansion. Concomitant administration of propranolol suppresses the first and second responses, and diuretics prevent the third. In treating chronic hypertension, vasodilators should be coadministered with both drugs. Potentiated in this fashion, well-tolerated doses of hydralazine (200 mg/day) can normalize the hemodynamics of most hypertensives. Guancydine and, particularly, minoxidil are promising antihypertensive vasodilators but remain in the investigative stages. Nitroprusside and diazoxide are powerful intravenous vasodilators and are effective for hypertensive emergencies. They differ in time course of action and in effect on cardiac output.



Author Affiliations

Boston

From the Hypertension and Clinical Pharmacology Unit, Department of Medicine and Pharmacology, Massachusetts General Hospital and Harvard Medical School, Boston.


Footnotes

Received for publication Oct 23,1973; accepted Jan 28, 1974.

Reprint requests to Massachusetts General Hospital, Boston, MA 02114 (Dr. Koch-Weser).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inhibitory Effects of AE0047, a New Dihydropyridine Ca2+ Channel Blocker, on Renal Nerve Stimulation-Induced Renal Actions in Anesthetized Dogs
Yamasaki et al.
J. Pharmacol. Exp. Ther. 2000;293:1040-1047.
ABSTRACT | FULL TEXT  

Combination of Converting Enzyme Inhibitor With Diuretic for the Treatment of Hypertension
Townsend and Holland
Arch Intern Med 1990;150:1175-1183.
ABSTRACT  

Hypertensive Emergencies and Urgencies
Ferguson and Vlasses
JAMA 1986;255:1607-1613.
ABSTRACT  

Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards
PACKER
ANN INTERN MED 1985;103:258-270.
ABSTRACT  

Acute Treatment of Hypertension With Slow Infusion of Diazoxide
Huysmans et al.
Arch Intern Med 1983;143:882-884.
ABSTRACT  

Short-term Therapy of Severe Hypertension: Hemodynamic Correlates of the Antihypertensive Response in Man
Sullivan et al.
Arch Intern Med 1979;139:1233-1239.
ABSTRACT  

Medical Management of Hypertension
Hutchinson
ANGIOLOGY 1979;30:558-567.
 

Nitroprusside Therapy for a Patient With a Pheochromocytoma
Lipson et al.
JAMA 1978;239:427-428.
ABSTRACT  

Plasma Renin Determination
Johnston
JAMA 1975;232:135-135.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1974 American Medical Association. All Rights Reserved.